Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 3
2000 7
2001 5
2002 14
2003 25
2004 40
2005 53
2006 62
2007 78
2008 56
2009 51
2010 62
2011 51
2012 33
2013 26
2014 24
2015 18
2016 14
2017 12
2018 14
2019 9
2020 14
2021 11
2022 8
2023 5
2024 10
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

619 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group. Kahn SE, et al. N Engl J Med. 2006 Dec 7;355(23):2427-43. doi: 10.1056/NEJMoa066224. Epub 2006 Dec 4. N Engl J Med. 2006. PMID: 17145742 Free article. Clinical Trial.
RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with metformin, and 34% with glyburide. This represents a risk reduction of 32% for rosiglitazone, as compared with metformin, and 63%, as c …
RESULTS: Kaplan-Meier analysis showed a cumulative incidence of monotherapy failure at 5 years of 15% with rosiglitazone, 21% with me …
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Morley LC, et al. Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6. Cochrane Database Syst Rev. 2017. PMID: 29183107 Free PMC article.
MAIN RESULTS: We assessed the interventions metformin, clomiphene citrate, metformin plus clomiphene citrate, D-chiro-inositol, rosiglitazone and pioglitazone. We compared these with each other, placebo or no treatment. ...There was no clear evidence of a difference in mis …
MAIN RESULTS: We assessed the interventions metformin, clomiphene citrate, metformin plus clomiphene citrate, D-chiro-inositol, rosiglita …
Rosiglitazone for type 2 diabetes mellitus.
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Richter B, et al. Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD006063. doi: 10.1002/14651858.CD006063.pub2. Cochrane Database Syst Rev. 2007. PMID: 17636824 Free PMC article.
MAIN RESULTS: Eighteen trials which randomised 3888 people to rosiglitazone treatment were identified. Longest duration of therapy was four years with a median of 26 weeks. ...New data on raised fracture rates in women reveal extensive action of rosiglitazone in var …
MAIN RESULTS: Eighteen trials which randomised 3888 people to rosiglitazone treatment were identified. Longest duration of therapy wa …
Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials.
Monami M, Lamanna C, Marchionni N, Mannucci E. Monami M, et al. Diabetes Care. 2008 Jul;31(7):1455-60. doi: 10.2337/dc07-2308. Epub 2008 Mar 28. Diabetes Care. 2008. PMID: 18375416 Free PMC article.
Considering differences in the duration of follow-up among treatment arms in some of the trials, we also calculated the incidence of cancer in rosiglitazone and control groups. RESULTS: Eighty trials, enrolling 16,332 and 12,522 patients in the rosiglitazone and com …
Considering differences in the duration of follow-up among treatment arms in some of the trials, we also calculated the incidence of cancer …
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Nissen SE, Wolski K. Nissen SE, et al. Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Arch Intern Med. 2010. PMID: 20656674 Review.
STUDY SELECTION: The study included all randomized controlled trials of rosiglitazone at least 24 weeks in duration that reported CV adverse events. DATA EXTRACTION: Odds ratios (ORs) for MI and mortality were estimated using a fixed-effects meta-analysis of 56 trials, whi …
STUDY SELECTION: The study included all randomized controlled trials of rosiglitazone at least 24 weeks in duration that reported CV …
[What about the controversy regarding rosiglitazone].
Scheen AJ, De Flines J, Paquot N. Scheen AJ, et al. Rev Med Liege. 2007 Sep;62(9):560-5. Rev Med Liege. 2007. PMID: 17966792 Free article. French.
The present article aims at summarizing the recent controversy about rosiglitazone (Avandia), an insulin sensitizer used as oral antidiabetic agent in the treatment of type 2 diabetes. We will present and briefly discuss 1) the results of the meta-analysis that raised susp …
The present article aims at summarizing the recent controversy about rosiglitazone (Avandia), an insulin sensitizer used as oral anti …
Effect of rosiglitazone on circulating malondialdehyde (MDA) level in diabetes based on a systematic review and meta-analysis of eight clinical trials.
Majidi Z, Hosseinkhani S, Amiri-Dashatan N, Emamgholipour S, Tutunchi S, Hashemi J, Ghorbani F, Koushki M. Majidi Z, et al. J Investig Med. 2021 Mar;69(3):697-703. doi: 10.1136/jim-2020-001588. Epub 2020 Dec 22. J Investig Med. 2021. PMID: 33408159
Patients with type 2 diabetes have high levels of malondialdehyde (MDA), and clinical data suggest a reducing effect of rosiglitazone (RSG) on the level of MDA in these patients. However, the results of available studies on the level of MDA in RSG-treated patients are not …
Patients with type 2 diabetes have high levels of malondialdehyde (MDA), and clinical data suggest a reducing effect of rosiglitazone …
Long-term risk of rosiglitazone on cardiovascular events - a systematic review and meta-analysis.
Cheng D, Gao H, Li W. Cheng D, et al. Endokrynol Pol. 2018;69(4):381-394. doi: 10.5603/EP.a2018.0036. Epub 2018 Jun 28. Endokrynol Pol. 2018. PMID: 29952413 Free article.
We included 11RCTs and four observational studies involving 20,079 individuals with T2DM allocated to rosiglitazone and a similar number to comparison groups of which only five compared rosiglitazone with placebo and collected data on cardiovascular outcomes. ...Alt …
We included 11RCTs and four observational studies involving 20,079 individuals with T2DM allocated to rosiglitazone and a similar num …
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Wallach JD, et al. BMJ. 2020 Feb 5;368:l7078. doi: 10.1136/bmj.l7078. BMJ. 2020. PMID: 32024657 Free PMC article.
OBJECTIVES: To conduct a systematic review and meta-analysis of the effects of rosiglitazone treatment on cardiovascular risk and mortality using multiple data sources and varying analytical approaches with three aims in mind: to clarify uncertainties about the cardiovascu …
OBJECTIVES: To conduct a systematic review and meta-analysis of the effects of rosiglitazone treatment on cardiovascular risk and mor …
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
Nissen SE, Wolski K. Nissen SE, et al. N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21. N Engl J Med. 2007. PMID: 17517853 Free article.
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. ...Despite these limitations, patients and providers should consider the potential for serious advers …
BACKGROUND: Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity …
619 results